Literature DB >> 3100097

Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay.

E Koren, P Puchois, P Alaupovic, J Fesmire, A Kandoussi, J C Fruchart.   

Abstract

We describe a method for measuring apolipoprotein A-I (ApoA-I) associated and unassociated with apolipoprotein A-II (ApoA-II) in plasma. To directly determine associated ApoA-I, we coated microtiter plates with antibody to ApoA-II, blocked the nonspecific binding sites, and incubated the plate with plasma, immobilizing the lipoprotein particles containing both ApoA-II and ApoA-I. The unbound constituents of plasma were washed away, peroxidase-labeled antibody to ApoA-I was added, the plate rewashed, peroxidase substrate added, and the resulting color measured. ApoA-I unassociated with ApoA-II was evaluated by subtracting the concentration of associated ApoA-I from the total ApoA-I concentration. The method is specific, rapid, and precise. Within- and between-assay CVs were 5.6 and 9.8%, respectively. Analytical recovery of ApoA-I was 94%. The average normolipidemic concentration of ApoA-I associated with ApoA-II in 50 women was 790 mg/L; in 50 men, it was 788 mg/L. The corresponding values for unassociated ApoA-I were 644, 577 mg/L. Both lipoprotein forms of ApoA-I were detected in all major density classes, but were most abundant in high-density lipoproteins. The technique is applicable to measurement of any two apolipoproteins that occur in both associated and unassociated forms in plasma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100097

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  11 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.

Authors:  Ju-Yi Hsieh; Chiz-Tzung Chang; Max T Huang; Chia-Ming Chang; Chia-Ying Chen; Ming-Yi Shen; Hsin-Yi Liao; Guei-Jane Wang; Chu-Huang Chen; Chao-Jung Chen; Chao-Yuh Yang
Journal:  Anal Chem       Date:  2013-11-13       Impact factor: 6.986

3.  The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study.

Authors:  J F Moreel; G Roizes; A E Evans; D Arveiler; J P Cambou; C Souriau; H J Parra; E Desmarais; J C Fruchart; P Ducimetière
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

4.  Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.

Authors:  J M Bard; G Luc; P Douste-Blazy; P Drouin; O Ziegler; B Jacotot; C Dachet; J L De Gennes; J C Fruchart
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Plasma lipid, lipoprotein and apolipoprotein profiles in Nigerian university athletes and non-athletes.

Authors:  O O Oyelola; M A Rufai
Journal:  Br J Sports Med       Date:  1993-12       Impact factor: 13.800

6.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

7.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.

Authors:  B Jacotot; J D Banga; P Pfister; M Mehra
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

9.  Genetic determination of plasma apolipoprotein AI in a population-based sample.

Authors:  P P Moll; V V Michels; W H Weidman; B A Kottke
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

10.  Metabolism of HDL apolipoprotein A-I and A-II in type 1 (insulin-dependent) diabetes mellitus.

Authors:  M R Taskinen; J Kahri; V Koivisto; J Shepherd; C J Packard
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.